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• The CDC vaccination timeline is shown below for immunocompromised patients greater
than 65 years of age if no prior PNA vaccine2:
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Diagnosis

• According to the CDC, rate of vaccination was 23.3% in adults aged 19-64 years at
increased risk of PNA and 69% among adults > 65 years in 2018.3
• Although recommended for immunosuppressed patients, PNA vaccination rates in IBD
patients are less than the general at-risk population.1,3
• Evidence shows specialty pharmacy services improve medication adherence, appropriate
medication use, and patient engagement; pharmacists at Parkview Health assist with
disease state management with self-injectable biologic therapies. This comprehensive
medication education includes recommending appropriate vaccines for all patients opted
into pharmacy services.4,5
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• The pharmacist-care group was more likely to be vaccinated against PNA; the biggest
difference was noted among patients who received PCV13 and PPSV23, further completing
the recommended regimen.
• During this study, visits were conducted via telemedicine or face-to-face due to the Covid19 pandemic, with fifty-nine percent of subjects engaging in both visit types. Vaccination
rates were not impacted between those seen solely in-person versus virtually, which
supports the continued use of a hybrid model.
• Vaccination rates do differ among specialists; reasons for this may include varying rates of
vaccine hesitancy, education provided, or provider/pharmacist interaction (Provider 3 works
primarily remote).
• Both study groups had higher rates of vaccination among patients less than sixty-five years
old when compared to national rates, with the pharmacist-group exhibiting greater benefit.3
• Covid-19 vaccination rates were consistent with state-wide vaccination rates.6
• Limitations consist of the following: inability to categorize “other” vaccines, lack of up-todate vaccination assessment, and impact of other care team members on vaccination rates.
• With PCV20 becoming the primary PNA vaccine, it is anticipated that vaccination rates will
increase among all age groups due to a less complex vaccine regimen and continued
pharmacist education within the clinic.
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METHODS
• The following study is a retrospective analysis of subjects with IBD managed by specialty
providers at Parkview Physicians Group Gastroenterology Clinic between April 1, 2020 and
May 31, 2022.
• Subjects were included if they had a diagnosis of Crohn’s disease or ulcerative colitis and
were prescribed monoclonal antibody therapy; biosimilars were included.
• Subjects were separated into a pharmacist-care group or a control group, managed
exclusively by their IBD specialist; this is considered standard of care.
• The pharmacist-care group included patients actively receiving adalimumab, golimumab,
certolizumab pegol, or ustekinumab; these patients received vaccine recommendations from
a Parkview specialty pharmacist.
• The control group, or provider group, included patients actively receiving infliximab or
vedolizumab.
• The primary endpoint consisted of PNA vaccination rate comparison between the
pharmacist-managed group and the control group.
• Subjects were split into the following categories based on their vaccination status: PCV13
only, PPSV23 only, both (PCV13 and PPSV23), none, other, and unknown; subjects were
considered vaccinated if they fell into one of the first three categories.
• Secondary endpoints included evaluation of differences between the two groups in
vaccination rates based on visit type, IBD specialist, and age.
• Covid vaccination compliance rates were compared as an additional secondary endpoint.
• Subjects were included in the vaccinated group if they received at least one dose of a
Covid-19 vaccine.
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• The purpose of this study is to assess the impact of clinical specialty pharmacy services and
education on compliance with vaccine recommendations in subjects with IBD.
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• Inflammatory bowel disease (IBD) is a chronic condition involving inflammation and ulcers
within the gastrointestinal tract; moderate to severe IBD typically requires biologic therapy
for treatment, resulting in immunosuppression.1
• The Centers for Disease Control and Prevention (CDC) recommends pneumococcal (PNA)
vaccination for adults 19-64 years old who have certain chronic medical conditions and are
immunocompromised, as well as all adults 65 years or older.1,2
• The CDC vaccination timeline is shown below for immunocompromised patients aged 19- 64
years2:
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